Patent SG-11201909334T-A (SG)
Title: Proteins for the treatment of epithelial barrier function disorders
Inventor: HAN ANDREW WONHEE
IPC: A61K35/74
Filed: 2018-04-06
Abstract: INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 11 October 2018 (11.10.2018) WIPO I PCT onion °nolo momiu Elmo oimIE (10) International Publication Number WO 2018/187682 Al (51) International Patent Classification: A61K 35/74 (2015.01) A61P 1/00 (2006.01) A61K 39/02 (2006.01) (21) International Application Number: PCT/US2018/026447 (22) International Filing Date: 06 April 2018 (06.04.2018) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/482,963 07 April 2017 (07.04.2017) US 62/607,706 19 December 2017 (19.12.2017) US 62/611,334 28 December 2017 (28.12.2017) US (71) Applicant: SECOND GENOME, INC. [US/US]; 341 Allerton Avenue, South San Francisco, California 94080 (US). (72) Inventors: HAN, Andrew Wonhee; c/o Second Genome, Inc., 341 Allerton Avenue, South San Francisco, Califor- nia 94080 (US). GOODYEAR, Andrew Whitman; c/o Second Genome, Inc., 341 Allerton Avenue, South San Francisco, California 94080 (US). GUJRAL, Tarunmeet; c/o Second Genome, Inc., 341 Allerton Avenue, South San Francisco, California 94080 (US). DESANTIS, Todd Zachary; c/o Second Genome, Inc., 341 Allerton Avenue, South San Francisco, California 94080 (US). DABBAGH, Karim; c/o Second Genome, Inc., 341 Allerton Avenue, South San Francisco, California 94080 (US). TAKEUCHI, Toshihiko; c/o Second Genome, Inc., 341 Allerton Avenue, South San Francisco, California 94080 (US). JIN, Ye; c/ o Second Genome, Inc., 341 Allerton Avenue, South San Francisco, California 94080 (US). WILLCOXON, Michi Izumi; c/o Second Genome, Inc., 341 Allerton Avenue, South San Francisco, California 94080 (US). BANAS, Ste- fanie; c/o Second Genome, Inc., 341 Allerton Avenue, South San Francisco, California 94080 (US). (74) Agent: HOLLY, David Christopher et al.; Cooley LLP, 1299 Pennsylvania Avenue, N.W., Suite 700, Washington, District of Columbia 20004 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Declarations under Rule 4.17: as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii)) as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii)) Published: with international search report (Art. 21(3)) before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h)) with sequence listing part of description (Rule 5.2(a)) (54) Title: PROTEINS FOR THE TREATMENT OF EPITHELIAL BARRIER FUNCTION DISORDERS (57) : The disclosure relates to therapeutic proteins and pharmaceutical compositions comprising said proteins, which have utility in treating various human diseases. In particular aspects, the disclosed therapeutic proteins are useful for treating human gas- trointestinal inflammatory diseases and gastrointestinal conditions associated with decreased epithelial cell barrier function or integri- ty. Further, the disclosed therapeutic proteins are useful for treating human inflammatory bowel disease, including inter alia, Crohn's disease and ulcerative colitis.